Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial

被引：0
|
作者：
Wu, Lingying [1 ]
Li, Ning [1 ]
Wang, Jing [2 ]
Li, Qingshui [3 ]
Wang, Danbo [4 ]
Tang, Junying [5 ]
Zhang, Cuiying [6 ]
Zhang, Guonan [7 ]
Hao, Min [8 ]
Yao, Desheng [9 ]
Duan, Wei [10 ]
Gao, Qinglei [11 ]
Wang, Li [12 ]
Zhang, Youzhong [13 ]
An, Ruifang [14 ]
Yin, Rutie [15 ]
Zhou, Qi [16 ]
Yang, Hongying [17 ]
Zhu, Jianqing [18 ]
Jiang, Kui [19 ]
Wu, Qiang [20 ]
Zhao, Weidong [21 ]
Huang, Yi [22 ]
Xia, Bairong [23 ]
Yang, Xinfeng [24 ]
Li, Bo [24 ]
机构：
[1] PUMC, Nat Canc Ctr, Canc Hosp, Chinese Acad Med Sci, Beijing, Peoples R China
[2] Hunan Canc Hosp, Changsha, Peoples R China
[3] Shandong First Med Univ, Affiliated Canc Hosp, Shandong, Peoples R China
[4] China Med Univ, Canc Hosp, Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[5] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[6] Inner Mongolia Peoples Hosp, Hohhot, Peoples R China
[7] Sichuan Canc Hosp, Chengdu, Peoples R China
[8] Shanxi Med Univ, Hosp 2, Taiyuan, Peoples R China
[9] Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China
[10] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing, Peoples R China
[11] HUST, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
[12] Henan Canc Hosp, Zhengzhou, Peoples R China
[13] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[14] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China
[15] Sichuan Univ, West China Hosp 2, Chengdu, Peoples R China
[16] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China
[17] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China
[18] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[19] Dalian Med Univ, Hosp 2, Dalian, Peoples R China
[20] Jiangsu Canc Hosp, Nanjing, Peoples R China
[21] Anhui Prov Hosp, Hefei, Peoples R China
[22] Hubei Canc Hosp, Wuhan, Peoples R China
[23] Anhui Prov Canc Ctr, Hefei, Peoples R China
[24] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
GYNECOLOGIC ONCOLOGY | 2024年 / 190卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
111
引用
收藏
页码：S74 / S75
页数：2
相关论文
共 50 条
  • [31] A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY OF GEFITINIB (G) VERSUS PLACEBO (P) IN PATIENTS (PTS) WITH ADVANCED NSCLC, NON-PROGRESSING AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY (EORTC 08021-ILCP)
    Surmont, V. F.
    Gaafar, R. M.
    Scagliotti, G. V.
    van Klaveren, R. J.
    Papamichael, D.
    Hasan, B.
    Torri, V.
    van Meerbeeck, J. P.
    ANNALS OF ONCOLOGY, 2010, 21 : 124 - 124
  • [32] Phase II study: Letrozole maintenance therapy after first-line chemotherapy in patients with advanced serous and endometrioid ovarian cancer
    Tyulyandina, A.
    Rumyantsev, A.
    Pokataev, I.
    Nechushkina, V.
    Morkhov, K.
    Sergeev, Y.
    Mochalnikova, V.
    Bulanov, A.
    Stenina, M.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study
    Ramalingam, Suresh S.
    Novello, Silvia
    Guclu, Salih Zeki
    Bentsion, Dmitry
    Zvirbule, Zanete
    Szilasi, Maria
    Bernabe, Reyes
    Syrigos, Konstantinos
    Byers, Lauren Averett
    Clingan, Philip
    Bar, Jair
    Vokes, Everett E.
    Govindan, Ramaswamy
    Dunbar, Martin
    Ansell, Peter
    He, Lei
    Huang, Xin
    Sehgal, Vasudha
    Glasgow, Jaimee
    Bach, Bruce A.
    Mazieres, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (32) : 3633 - +
  • [34] Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review
    Tissera, Natalia Soledad
    Balconi, Francesca
    Garcia-Alvarez, Alejandro
    Cubero, Jorge Hernando
    O'Connor, Juan Manuel
    Chacon, Matias
    Capdevila, Jaume
    CANCER TREATMENT REVIEWS, 2025, 132
  • [35] A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial
    Maluf, Fernando Cotait
    Trindade, Karine
    Almeida Preto, Daniel D.
    Marques Monteiro, Fernando Sabino
    Luz, Murilo
    Beato, Patricia Milhomem
    Bastos, Diogo Assed
    Holanda Soares, Joao Paulo
    Lopes dos Santos, Victor Marcondes
    Werneck De Carvalho, Luis Eduardo
    Borges Muniz, David Queiroz
    Racy, Douglas
    Halabi, Susan
    Rebelatto, Taiane Francieli
    Werutsky, Gustavo
    de Jesus, Rafaela Gomes
    Fay, Andre P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] NEOADJUVANT CHEMOTHERAPY MAY IMPAIR RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY FOR OVARIAN CANCER PATIENTS
    Ekmann-Gade, A. W.
    Hogdall, C.
    Peen, U. B. S.
    Engelholm, S. A.
    Fago-Olsen, C. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 675 - 676
  • [37] Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02
    Sahai, Vaibhav
    Griffith, Kent A.
    Goff, Laura Williams
    Crysler, Oxana V.
    Enzler, Thomas
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial
    Sabbatini, P.
    Berek, J. S.
    Casado, A.
    Cwiertka, K.
    Pinter, T.
    Pluzanska, A.
    Scambia, G.
    Pujade-Lauraine, E.
    Vermorken, J. B.
    Pfisterer, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Biomarker testing to guide first-line PARP inhibitor maintenance for patients with advanced ovarian cancer after response to first-line platinum chemotherapy: A cost-effectiveness study
    Fan, Lin
    Elsea, David
    Muston, Dominic
    Mihai, Adela
    Monberg, Matthew
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S195 - S195
  • [40] MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)
    Gupta, Shilpa
    Ballman, Karla V.
    Galsky, Matt D.
    Morris, Michael J.
    Chen, Ronald C.
    Chan, Timothy A.
    Dercle, Laurent
    Wen, Yujia
    Sridhar, Srikala S.
    Yen, Aihua Edward
    Grivas, Petros
    Tan, Alan
    Baghaie, Shiva
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345